

**RECENT PROGRESS AND CURRENT
CONTROVERSIES IN MANAGEMENT OF
SMALL CELL LUNG CANCER**

Essay Submitted For The Partial Fulfillment of
The Master Degree In Radiation Oncology And Nuclear Medicine

By

Ahmed Ezzat Ahmed Essa

M.B., B.Ch.

Supervised By

Prof. Dr. Safwa Massoud Ibrahim

Professor of Radiation Oncology and Nuclear Medicine
Faculty of Medicine, Ain Shams University

Dr. Mohamed Essam Saleh

Lecturer of Radiation Oncology and Nuclear Medicine
Faculty of Medicine, Ain Shams University

**Faculty of Medicine
Ain Shams University**

1998



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

**قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا،
إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ**

صدق الله العظيم

سورة البقرة- الآية: ٣٢


Acknowledgment

First of all thanks to God , without his help this work could not be accomplished ..

*Words stand short when coming to express my gratitude and appreciation to **Prof. Dr. Salwa Masoud Ibrahim** , Professor of Radiation Oncology and Nuclear Medicine , Ain Shams University , she saved no time or effort in revising this work, her continuous support , guidance and valuable remarks were of paramount importance to accomplish this work . Whatever have been said , will be little to express my thanks for her .*

*I would like also to thank **Dr. Mohamed Essam Saleh** ,Lecturer of Radiation Oncology and Nuclear Medicine , Ain shams University , for his continuous support, fruitful guidance, meticulous supervision and worthy advises.*

Ahmed Ezzat



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

List of Figures

Fig. No.	Title	Page
1	The bronchi and bronchopulmonary semngnets	10
2	Lymphatic drainage of both lungs	14
3	Surface anatomy of lungs and pleura	17
4	Relative frequency of respiratory system malignancies in Egypt	21
5	Relative frequency of lung cancer to total malignancy in Ain Shams University Department of Radiation Oncology and Nuclear Medicine	22
6	Relative frequency of respiratory system malignancy to total cancer cases in NEMROCK	23
7	Incidence and mortality reported from lung cancer in Europe	27
8	Relative risk of lung cancer versus daily consumption of cigarettes	31
9	Relative risk of lung cancer versus duration of stopping smoking	31
10	SCLC pathological specimen	36
11, 12, 13	SCLC microscopic appearance	37,38
14	SCLC-Electron micrographic picture	40
15	Microscopic appearance of SCLC mixed type	41
16	Lung cancer staging system	55

17	Anatomic stage grouping	56
18	Frequent manifestations of bronchogenic carcinoma	61
19	Hypertrophic perostitis of lower legs	67
20	Cutaneous metastases	70
21	Plain X-ray chest of SCLC	74
22	A scheme for the diagnostic procedures of SCLC	74
23	CT scan of pancoast tumor	76
24	MRI of pancoast tumor	78
25	Axial PET image of SCLC mass	79
26	Fiberoptic bronchoscopy of SCLC patient	82
27	Bone metastases of SCLC patient	85
28	Bone marrow biopsy shows bone marrow metastases	86
29	Brain metastases in autopsy specimens	88
30	Liver metastases in a SCLC patient	89
31	CT scan shows liver metastases in a SCLC patient	90
32	CT scan shows renal metastases in a SCLC patient	90
33	CT scan of adrenal metastases	91
34 , 35	Chest radiography of responding patient to combination chemotherapy and mediastinal irradiation	110 111
36	Scheme for high-dose chemotherapy supported by PBPC and filgrastim	126

37	Prolonged survival associated with reduction of VICE cycle interval	127
38	Improvement in progression free survival associated with maintenance chemotherapy	131
39	CT planning system for bronchogenic carcinoma	157
40	Simulator film for SCLC planning	157
41	Dose distribution from parallel opposing fields to the mediastinum	161
42	Isodose curves of a treatment plan	161
43	Three fields arrangement for irradiating peripheral SCLC	163
44	Three fields arrangement for irradiating peripheral SCLC	163
45	Three fields arrangement for irradiating central SCLC	164
46	Regional ED-SCLC	183
47	Port film for PCI	189
48	Survival in SCLC	230

List of Tables

Tab. No.	Title	Page
1	No. of lung cancer cases in relation to total lung cancer cases in Ain Shams University Department of Radiation Oncology and Nuclear Medicine	22
2	WHO histologic classification of epithelial bronchogenic carcinoma	35
3	Biologic properties of lung cancer cell lines	50
4	Lung cancer staging	57
5	Symptoms and signs associated with lung cancer	59
6	Pulmonary function tests	80
7	Screening methods for lung cancer	94
8	Cytotoxic drugs for SCLC	97
9	New single agents with activity in SCLC	103
10	New active agents for SCLC	106
11	conventional combination regimens used in SCLC	109
12	Carboplatin/Etoposide regimens used in SCLC treatment	113
13	Comparison of combination chemotherapy with oral etoposide in SCLC treatment	116

14	Dose escalation for cisplatin/etoposide/ paclitaxel in ED-SCLC	117
15	New combination chemotherapy in SCLC	118
16	Carboplatin/paclitaxel regimens for SCLC	120
17	Survival benefit according to dose of combination chemotherapy	123
18	Results of standard versus high dose combination chemotherapy	124
19	Recent randomized trials of maintenance chemotherapy in SCLC	130
20	Oral etoposide in poor performance status SCLC patients	133
21	Carboplatin and etoposide in elderly and medically compromised patients	134
22	Randomized trials of late intensification in SCLC	136
23	Randomized trials of alternating chemotherapy regimens versus each regimen alone in SCLC	141
24	Grading of acute and subacute toxicity of chemotherapy (WHO criteria)	146
25	percentage of patients with WHO grade 3 or greater toxicity	152
26	Combined PE-radiation therapy in LD-SCLC	179